
BIOKEMIX WORLDWIDE LTD

UNAUDITED

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 APRIL 2020

BIOKEMIX WORLDWIDE LTD
REGISTERED NUMBER: 09547901

BALANCE SHEET
AS AT 30 APRIL 2020

	Note	2020 £	2019 £
Fixed assets			
Investments	4	69,709	-
		<u>69,709</u>	<u>-</u>
Current assets			
Debtors: amounts falling due within one year	5	200,296	-
Cash at bank and in hand	6	96,207	1
		<u>296,503</u>	<u>1</u>
Creditors: amounts falling due within one year	7	(216,633)	-
Net current assets		<u>79,870</u>	<u>1</u>
Total assets less current liabilities		<u>149,579</u>	<u>1</u>
Net assets		<u><u>149,579</u></u>	<u><u>1</u></u>
Capital and reserves			
Called up share capital		1,089	1
Share premium account		164,131	-
Profit and loss account		(15,641)	-
		<u>149,579</u>	<u>1</u>

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by:

BIOKEMIX WORLDWIDE LTD
REGISTERED NUMBER: 09547901

BALANCE SHEET (CONTINUED)
AS AT 30 APRIL 2020

.....
Sameer Bajaj

Director

Date: 30 April 2021

The notes on pages 3 to 7 form part of these financial statements.

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2020**

1. General information

Biokemix Worldwide Ltd is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address are as below:

Registered number: 09547901

Registered office: 1 Doughty Street, London, United Kingdom, WC1N 2PH.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The following principal accounting policies have been applied:

2.2 Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

2.3 Borrowing costs

All borrowing costs are recognised in profit or loss in the year in which they are incurred.

2.4 Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

Investments in unlisted Company shares, whose market value can be reliably determined, are remeasured to market value at each balance sheet date. Gains and losses on remeasurement are recognised in the Statement of comprehensive income for the period. Where market value cannot be reliably determined, such investments are stated at historic cost less impairment.

2.5 Debtors

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

2.6 Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2020**

2. Accounting policies (continued)**2.7 Creditors**

Short term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

2.8 Financial instruments

The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares.

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Statement of comprehensive income.

For financial assets measured at amortised cost, the impairment loss is measured as the difference between an asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If a financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between an asset's carrying amount and best estimate of the recoverable amount, which is an approximation of the amount that the Company would receive for the asset if it were to be sold at the balance sheet date.

Financial assets and liabilities are offset and the net amount reported in the Balance sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

3. Employees

The average monthly number of employees, including directors, during the year was 0 (2019 - 0).

4. Fixed asset investments

	Investments in subsidiary companies £
Cost or valuation	
Additions	69,709
	<hr/>
At 30 April 2020	<u><u>69,709</u></u>

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2020**

5. Debtors

	2020	<i>2019</i>
	£	£
Amounts owed by group undertakings	200,296	-
	<u>200,296</u>	<u>-</u>

6. Cash and cash equivalents

	2020	<i>2019</i>
	£	£
Cash at bank and in hand	96,207	1
	<u>96,207</u>	<u>1</u>

7. Creditors: Amounts falling due within one year

	2020	<i>2019</i>
	£	£
Other loans	122,973	-
Amounts owed to group undertakings	86,692	-
Other creditors	1,845	-
Accruals and deferred income	5,123	-
	<u>216,633</u>	<u>-</u>

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2020

8. Loans

Analysis of the maturity of loans is given below:

	2020 £	2019 £
Amounts falling due within one year		
Other loans	122,973	-
	<u>122,973</u>	<u>-</u>
	<u>122,973</u>	<u>-</u>

9. Financial instruments

	2020 £	2019 £
Financial assets		
Financial assets measured at fair value through profit or loss	<u>96,207</u>	<u>1</u>

Financial assets measured at fair value through profit or loss comprise cash at bank and hand.

10. Related party transactions

Sameer Bajaj is the common director of Auric SKB Ltd, Scientest Biokemix Gmbh and Biokemix Worldwide Ltd.

As on 30 April 2020, Company has a loan due to Auric SKB Ltd of £40,919 and Scientest biokemix gmbh has a loan payable to company of £200,296.

As on 30 April 2020, Transene Company, Inc hold shares of Biokemix Worldwide Ltd and company owed £45,773 to Transene Company, Inc.

Included in other creditor is amount owed to Sameer Bajaj of £1,845.

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2020**

11. Controlling party

Auric SKB Ltd (Company No. 11985640) is ultimate parent company of the group. Its registered office address is 14 Old Queen Street, London, England, SW1H 9HP.

Exemption from preparation of consolidated financial statement

The company is part of small group and are not required by the act to prepare consolidated financial statements.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.